Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed by Immunomedics, Inc.
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.128.200.132